Skip to main content
Premium Trial:

Request an Annual Quote

Protein Design Labs Posts 74% Revenue Jump in Q3; Expects Breakeven in End 01

NEW YORK, Nov. 2 - Protein Design Labs has reported a narrower-than-expected third-quarter loss on a 74 percent spike in revenues, the company said.

The company, which develops humanized monoclonal antibodies, posted a net loss for the period ended Sept. 30 of $1.8 million, or 2 cents per basic and diluted share, compared with net loss of $5.1 million, or 6 cents per share, in 2000.

A consensus estimate of Wall Street analysts polled by Thomson Financial/First Call expected a loss of 5 cents per share.

Third-quarter revenues rose 74 percent to $16.7 million from $9.6 million in the same quarter 2000. Total costs and expenses were $18.4 million, compared with $14.7 million one year earlier.

Looking ahead, the Fremont, Calif.-based company said on Thursday that it expects to approach break-even or slightly positive results by the end of the year, despite costs and expenses rising by between 20 percent to 25 percent.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.